Athirah Bakhtiar

Athirah Bakhtiar
Monash University (Malaysia) · School of Pharmacy

Doctor of Philosophy

About

16
Publications
4,138
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
92
Citations
Additional affiliations
June 2019 - June 2019
Monash University (Malaysia)
Position
  • Lecturer
January 2013 - January 2016
Monash University (Malaysia)
Position
  • PhD

Publications

Publications (16)
Article
Full-text available
Inappropriate use of antibiotics has been shown to contribute to the occurrence of multidrug-resistant organisms (MROs). A surveillance study was performed in the largest tertiary care hospital in Kuala Lumpur, Malaysia, from 2018 to 2020 to observe the trends of broad-spectrum antibiotics (beta-lactam/beta-lactamases inhibitors (BL/BLI), extended-...
Article
Full-text available
Purpose Gene therapy is a promising and novel therapeutic strategy for many mutated gene-associated diseases, including breast cancer. However, it poses significant biological drawbacks such as rapid clearance from the circulatory system and low cellular uptake of the exogenously delivered functional nucleic acids. The development of efficient and...
Article
PurposeLow efficacy of parenteral administration of naked therapeutic genes is associated with the presence of biological barriers including circulatory monocytes that clear and eliminate foreign materials via reticuloendothelial system. Chemically synthesized inorganic strontium nanoparticles (SNPs) present a way to improve the delivery of genetic...
Article
Full-text available
Mycobacterium tuberculosis (Mtb) is the microorganism that causes tuberculosis. This infectious disease has been around for centuries, with the earliest record of Mtb around three million years ago. The discovery of the antituberculosis agents in the 20th century has managed to improve the recovery rate and reduce the death rate tremendously. Howev...
Article
Full-text available
Cancer is associated with single or multiple gene defects. Recently, much research has focused on incorporating genetic materials as one of the means to treat various types of carcinomas. RNA interference (RNAi) conveys an alternative genetic approach for cancer patients, especially when conventional medications fail. RNAi involves the inhibition o...
Article
Full-text available
Genetic intervention via the delivery of functional genes such as plasmid DNA (pDNA) and short-interfering RNA (siRNA) offers a great way to treat many single or multiple genetic defects effectively, including mammary carcinoma. Delivery of naked therapeutic genes or siRNAs are, however, short-lived due to biological clearance by scavenging nucleas...
Article
Full-text available
Triple negative breast cancer (TNBC) is one of the most aggressive types of breast cancer. Owing to the absenteeism of hormonal receptors expressed at the cancerous breast cells, hormonal therapies and other medications targeting human epidermal growth factor receptor 2 (HER2) are ineffective in TNBC patients, making traditional chemotherapeutic ag...
Article
Full-text available
Inorganic nanoparticles hold great potential in the area of precision medicine, particularly for treating cancer owing to their unique physicochemical properties, biocompatibility and improved pharmacokinetics properties compared to their organic counterparts. Here we introduce strontium sulfite nanoparticles as new pH-responsive inorganic nanocarr...
Article
Full-text available
Genetic manipulation of cancer cells through intracellular delivery of plasmid DNA (pDNA) and short-interfering RNA (siRNA) would be an attractive approach for effectively treating various cancers with minimal adverse effects. However, naked DNA or siRNA is rapidly degraded by nucleases and exhibits low cellular uptake with resultant poor transfect...
Poster
Full-text available
Poster Presentation representing Monash University
Article
Full-text available
Conventional therapies for malignant cancer such as chemotherapy and radiotherapy are associated with poor survival rates owing to the development of cellular resistance to cancer drugs and the lack of targetability, resulting in unwanted adverse effects on healthy cells and necessitating the lowering of therapeutic dose with consequential lower ef...
Article
Full-text available
Cervical cancer is the second most common cancer and fourth leading cause of cancer-related deaths among women. Advanced stage of the disease is treated with radiation therapy and chemotherapy with poor therapeutic outcome and adverse side effects. NFκB, a well-known transcription factor in the control of immunity and inflammation, has recently eme...
Article
Full-text available
RNA interference (RNAi) is a powerful approach in functional genomics to selectively silence messenger mRNA (mRNA) expression and can be employed to rapidly develop potential novel drugs against a complex disease like cancer. However, naked siRNA being anionic is unable to cross the anionic cell membrane through passive diffusion and therefore, del...

Network

Cited By

Projects

Project (1)
Project
1. To investigate the combined roles of tumour suppressor genes and siRNAs-targeting oncogenes (MAPK or PI-3 kinase pathway regulatory genes and anti-apoptotic genes) on promoting growth inhibition, survival and chemoresistance of breast cancer cells in the presence of traditional anti-cancer agents (cyclophosphamide, doxorubicin and paclitaxel). 2. To understand the mechanism of synergistic effect for induction of apoptosis in breast cancer cells by nanoparticle-facilitated delivery of p53, oncogene-targeted siRNAs and conventional anti-cancer drugs. 3. To explore how enhanced therapeutic response can be achieved with low doses of anticancer drugs upon co-delivery with nanoparticle assisted p53 genes and siRNA targeting oncogenes in the breast cancer cells.